Posted by Michael Wonder on 22 Aug 2022
Minerva Neurosciences submits new drug application to FDA for roluperidone for the treatment of negative symptoms in patients with schizophrenia
22 August 2022 - Minerva Neurosciences today announced that the company has submitted a new drug application to the US FDA for roluperidone for the treatment of negative symptoms in patients with schizophrenia.
The roluperidone clinical development program aims to provide effective treatment for negative symptoms of schizophrenia, a significant unmet medical need in a large patient population.
